Participants in the analysis received a memory test. The test started with simple questions and became more challenging increasingly. While the test was being taken by them, they were given an MRI brain scan. The experts could see an increase in the experience in the brain through the test in both control group and those who acquired chemotherapy. There is measurably much less activity in the people who’d got chemotherapy. Kristin Campbell, a co-employee professor in the Section of Physical Therapy and innovator of the research team, said: ‘Physicians now recognize that the effects of cancer treatment persist long after its over and these effects can really impact a person’s existence.’ She also felt these findings may help healthcare providers test and measure the ramifications of chemotherapy on the brain..The EMA's Orphan Drug designation for CF102 is the latest in some catalysts that we believe are accelerating the clinical development route of our liver malignancy drug towards market approval. As we actively recruit patients in our Phase II study of CF102 in Europe, we are delighted the EMA will support CF102 through process assistance and post-authorization market exclusivity, stated Can-Fite CEO Dr. Pnina Fishman. Related StoriesNew RNA test of blood platelets may be used to identify location of cancerMeat-rich diet may increase kidney malignancy riskMD Anderson study reveals why chemotherapy medications not effective for most pancreatic tumor patientsIn the U.S., CF102 has already received Fast Track Designation as another line for the treatment of HCC of patients who’ve previously received Nexavar and Orphan Medication Designation for the treatment of HCC.